CN112752582A - 利用达格列净治疗射血分数降低的心力衰竭的方法 - Google Patents

利用达格列净治疗射血分数降低的心力衰竭的方法 Download PDF

Info

Publication number
CN112752582A
CN112752582A CN202080000531.4A CN202080000531A CN112752582A CN 112752582 A CN112752582 A CN 112752582A CN 202080000531 A CN202080000531 A CN 202080000531A CN 112752582 A CN112752582 A CN 112752582A
Authority
CN
China
Prior art keywords
patient
sglt2 inhibitor
administration
heart failure
dapagliflozin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080000531.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·M·兰吉尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN202011290859.2A priority Critical patent/CN112336713B/zh
Priority to CN202411075455.XA priority patent/CN118948830A/zh
Publication of CN112752582A publication Critical patent/CN112752582A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
CN202080000531.4A 2019-08-30 2020-03-09 利用达格列净治疗射血分数降低的心力衰竭的方法 Pending CN112752582A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202011290859.2A CN112336713B (zh) 2019-08-30 2020-03-09 达格列净在制备治疗射血分数降低的心力衰竭的药物中的用途
CN202411075455.XA CN118948830A (zh) 2019-08-30 2020-03-09 利用达格列净治疗射血分数降低的心力衰竭的方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962893849P 2019-08-30 2019-08-30
US62/893,849 2019-08-30
US201962930673P 2019-11-05 2019-11-05
US62/930,673 2019-11-05
US201962946625P 2019-12-11 2019-12-11
US62/946,625 2019-12-11
US202062960756P 2020-01-14 2020-01-14
US62/960,756 2020-01-14
US202062969181P 2020-02-03 2020-02-03
US62/969,181 2020-02-03
US202062985407P 2020-03-05 2020-03-05
US62/985,407 2020-03-05
PCT/EP2020/056211 WO2021037400A1 (en) 2019-08-30 2020-03-09 Methods of treating heart failure with reduced ejection fraction with dapagliflozin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202411075455.XA Division CN118948830A (zh) 2019-08-30 2020-03-09 利用达格列净治疗射血分数降低的心力衰竭的方法
CN202011290859.2A Division CN112336713B (zh) 2019-08-30 2020-03-09 达格列净在制备治疗射血分数降低的心力衰竭的药物中的用途

Publications (1)

Publication Number Publication Date
CN112752582A true CN112752582A (zh) 2021-05-04

Family

ID=69784449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080000531.4A Pending CN112752582A (zh) 2019-08-30 2020-03-09 利用达格列净治疗射血分数降低的心力衰竭的方法

Country Status (18)

Country Link
US (3) US10973836B2 (https=)
EP (1) EP4021507A1 (https=)
JP (4) JP7756487B2 (https=)
KR (3) KR102359799B1 (https=)
CN (1) CN112752582A (https=)
AU (4) AU2020202887B2 (https=)
BR (1) BR112020008705A2 (https=)
CA (1) CA3079175A1 (https=)
CL (1) CL2020001335A1 (https=)
CR (1) CR20200224A (https=)
IL (1) IL274020A (https=)
JO (1) JOP20200098A1 (https=)
MX (2) MX2020005388A (https=)
PE (1) PE20211267A1 (https=)
PH (1) PH12020551141A1 (https=)
SG (1) SG11202003971RA (https=)
TW (3) TWI786398B (https=)
WO (1) WO2021037400A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
EP4138826A1 (en) * 2020-04-22 2023-03-01 Bayer Aktiengesellschaft Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
US20240100013A1 (en) * 2021-01-04 2024-03-28 Lexicon Pharmaceuticals, Inc. Sotagliflozin for improving left atrial function
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
JP7396579B2 (ja) * 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物
WO2023175573A1 (en) * 2022-03-17 2023-09-21 Zydus Lifesciences Limited Pharmaceutical compositions comprising a β-blocker and an sglt2 inhibitor
US20250205317A1 (en) * 2022-03-28 2025-06-26 University Of Maryland, Baltimore Methods and compositions for the treatment of stroke
CR20250112A (es) * 2022-09-01 2025-08-18 Aztrazeneca Ab Combinación de ihnibidores de sglt2 y moduladores del receptor mineralcorticoide para usar en el tratamiento de enfermedades cardiorrenales
EP4640213A1 (en) * 2022-12-20 2025-10-29 THPharm Corp. Oral pharmaceutical preparation comprising sodium-glucose cotransporter-2 inhibitor and angiotensin ii receptor blocker

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2007093610A1 (en) 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TW200904454A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
AR065809A1 (es) * 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
JP2011506363A (ja) 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全の処置および／または予防用のオキサゾリジノン類
CA2812016A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
MX367404B (es) 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
JP2017528499A (ja) * 2014-09-25 2017-09-28 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 肝臓の疾患を治療するためのオメガ３脂肪酸とｓｇｌｔ−２阻害薬との併用剤
AU2017233889B2 (en) 2016-03-16 2022-07-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising empagliflozin and uses thereof
EP3508222A4 (en) * 2016-08-30 2020-04-29 Niigata University MEDICINES FOR REMOVING AGED CELLS
WO2018142422A1 (en) 2017-02-02 2018-08-09 Indoco Remedies Limited Process for the preparation of dapagliflozin
KR101943382B1 (ko) 2017-09-19 2019-01-29 오토텔릭바이오 주식회사 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
BR112021000139A2 (pt) 2018-07-19 2021-04-06 Astrazeneca Ab Métodos de tratamento da hfpef empregando dapagliflozina e composições compreendendo a mesma
WO2021037400A1 (en) 2019-08-30 2021-03-04 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
TW202220672A (zh) * 2020-07-27 2022-06-01 瑞典商阿斯特捷利康公司 用達格列淨治療慢性腎臟病之方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONALD E KOHAN等: "Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control" *
JOHN J.V. MCMURRAY等: "A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)" *

Also Published As

Publication number Publication date
US20210260083A1 (en) 2021-08-26
TW202335668A (zh) 2023-09-16
JP2023025207A (ja) 2023-02-21
JOP20200098A1 (ar) 2021-02-28
TW202108134A (zh) 2021-03-01
CL2020001335A1 (es) 2021-07-09
US20240216404A1 (en) 2024-07-04
TWI786398B (zh) 2022-12-11
IL274020A (en) 2021-03-01
BR112020008705A2 (pt) 2022-03-22
WO2021037400A1 (en) 2021-03-04
KR102359799B1 (ko) 2022-02-09
KR20210027229A (ko) 2021-03-10
AU2021215150A1 (en) 2021-09-02
PE20211267A1 (es) 2021-07-19
CA3079175A1 (en) 2021-02-28
SG11202003971RA (en) 2021-04-29
KR20220044234A (ko) 2022-04-07
TWI859649B (zh) 2024-10-21
AU2023210548A1 (en) 2023-08-17
US20210060043A1 (en) 2021-03-04
AU2020202887A1 (en) 2021-03-18
US11903955B2 (en) 2024-02-20
AU2021215150B2 (en) 2023-05-04
MX2020005388A (es) 2022-10-25
AU2025204486A1 (en) 2025-07-03
JP7494277B2 (ja) 2024-06-03
JP2025108488A (ja) 2025-07-23
AU2023210548B2 (en) 2025-04-17
CR20200224A (es) 2021-05-26
AU2020202887B2 (en) 2021-05-20
JP2022530575A (ja) 2022-06-30
PH12020551141A1 (en) 2021-05-31
US10973836B2 (en) 2021-04-13
EP4021507A1 (en) 2022-07-06
JP7756487B2 (ja) 2025-10-20
TW202504616A (zh) 2025-02-01
MX2022008018A (es) 2022-07-27
KR20240166611A (ko) 2024-11-26
JP2024119842A (ja) 2024-09-03

Similar Documents

Publication Publication Date Title
JP7494277B2 (ja) ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
Anker et al. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension
Seferović et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure
JP7161405B2 (ja) エンパグリフロジンを含む医薬組成物及びその使用
TW202216147A (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
HK40046452A (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
HK40051086A (en) Methods of treating heart failure with reduced ejection fraction with dapagliflozin
HK40046452B (en) Use of treating heart failure with reduced ejection fraction with dapagliflozin
CN112336713B (zh) 达格列净在制备治疗射血分数降低的心力衰竭的药物中的用途
Alicic et al. 3-Diabetic Kidney Disease
HK40117723A (zh) 利用达格列净治疗射血分数降低的心力衰竭的方法
EA042257B1 (ru) Способы лечения сердечной недостаточности со сниженной фракцией выброса с помощью дапаглифлозина
BR122025016233A2 (pt) Usos de composições farmacêuticas que compreendem um inibidor do sglt2
Afshinnia et al. Approach to Chronic Kidney Disease in the Diabetic Patient
TW202602436A (zh) 用於治療心臟衰竭之醛固酮合成酶抑制劑
Jaisser Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
Huang et al. De novo aortopathy and cardiovascular outcomes in paediatric liver transplant recipients

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051086

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination